Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.96 USD | -0.33% | -7.43% | -.--% |
21/05 | Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer | CI |
14/05 | Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 321.4 | - | - |
Enterprise Value (EV) 1 | -28.87 | 44.83 | 321.4 |
P/E ratio | -3.84 x | -3.72 x | -2.29 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | - | - | - |
EV / FCF | 0.52 x | -0.61 x | -3.53 x |
FCF Yield | 194% | -165% | -28.3% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 26,876 | - | - |
Reference price 2 | 11.96 | 11.96 | 11.96 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -37.81 | -63.6 | -92.62 | -148 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -36.3 | -64.83 | -91.25 | -171 |
Net income 1 | -27.71 | -36.3 | -61.47 | -87.55 | -138.4 |
Net margin | - | - | - | - | - |
EPS 2 | -8.051 | -9.730 | -3.115 | -3.215 | -5.213 |
Free Cash Flow 1 | - | - | -56 | -74 | -91 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 22/11/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -11.76 | -14.39 | -16.5 | -17.4 | -15.9 | - | - |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -11.22 | -13.42 | -14 | -15.05 | -16.95 | - | - |
Net income 1 | -11.22 | -13.42 | -15.16 | -16.09 | -16.58 | -17.68 | -19.37 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -6.700 | -0.7600 | -0.6733 | -0.7067 | -0.6700 | -0.6600 | -0.7200 |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 21/03/24 | 14/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | - | 350 | 277 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | - | -56 | -74 | -91 |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | - | 0.6 | 0.6 | 1 |
Capex / Sales | - | - | - | - | - |
Announcement Date | 22/11/23 | 21/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-.--% | 321M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+36.78% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ANRO Stock
- Financials Alto Neuroscience, Inc.